Preliminary Phase 2 data presented in November at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting showed that a combination of AU-007 and low-dose, subcutaneous aldesleukin is ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

The research teams led by Wolfgang Kastenmüller and Georg Gasteiger utilized advanced microscopy techniques to investigate ...

The research groups led by Wolfgang Kastenmüller and Georg Gasteiger employed innovative microscopy techniques to observe how ...

Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and ...

A team from the Max Planck Research Group for Systems Immunology at the University of Würzburg has identified a previously ...

The granted patents titled “System and Methods For Immune Cells Expansion and Activation In Large Scale” focus on a system and method for culturing and/or activating immune cells in a large scale, ...

A team from the Max Planck Research Group for Systems Immunology at the University of Würzburg has identified a previously ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate ...

Two new studies in Nature report on how effector memory-like CD8 + T cells infiltrate inflamed tissues in various disease states and drive tissue-restricted complement activation via the release ...